An observational study in Acne Vulgaris, sponsored by The First Affiliated Hospital with Nanjing Medical University. Completed at 1 site in China. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by The First Affiliated Hospital with Nanjing Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Acne Vulgaris with a site in China — 8 open to participants now, 10 under way, 2 of them phase 3. Acne Vulgaris · China.
Among the 35 studies in Acne Vulgaris with a site in China, this one is the only one that started in 2023, is one of 2 observational ones, and was the 35th registered.
795 studies on the registry are indexed under Acne Vulgaris; 96 are open to participants now.
Browse Acne Vulgaris studies →8 of the 35 studies in Acne Vulgaris with a site in China are open now. Recruiting first, the newest first:
Shenzhen People's Hospital · Sites in China
Ages 18–33
Shenyang Medical College · Sites in China
Ages 18–40
Shanghai Zhongshan Hospital · Sites in China
Ages 18–40
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. · Sites in China
Ages 12+
Xiyuan Hospital of China Academy of Chinese Medical Sciences · Sites in China
Ages 18–50
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 48 Acne Vulgaris studies recruiting now, 17 (35%) set no upper age limit and 30 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 6 · Phase 3 8 · Phase 4 1
First in 2008; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is below the median of 89 across 96 observational studies indexed under Acne Vulgaris.
Median enrollment 100 across the 33 interventional studies, 190 across the 2 observational. Of the 18 that completed or were terminated, 2 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 35 have an industry lead sponsor. The 10 most frequent:
The First Affiliated Hospital with Nanjing Medical University is the lead sponsor of 569 studies on the registry; 317 are open to participants now.
The First Affiliated Hospital with Nanjing Medical University has 1 study filed under Acne Vulgaris — fewer than ten, so there is no comparison to draw.
2 of the studies in Acne Vulgaris with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07186413Phase 3Galderma R&DA Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris | 2026-12-31 |
| NCT06763367Nanjing First Hospital, Nanjing Medical UniversityClinical Evaluation and Study of the Efficacy of a Centella Asiatica-Infused Facial Mask on Discosmetic Dermatosis | 2026-11-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 35 studies in Acne Vulgaris with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to evaluate the efficacy and safety of winona barrier special cream in post-acne erythema(PAE). The main questions it aims to answer are: whether winona barrier special cream can improve facial skin erythema, transepidermal water loss, water content of stratum corneum, pH,melanin, lipidomic and microbiodemic in patients with PAE .
type of study:clinical trial participant population/health conditions The study proposes to recruit 60 PAE patients and 20 healthy individuals The checks of patients were randomly selected to use winona barrier special cream on one side and the Basal Water on the other side. the sampes of surface skin are collected on week0, week4 and week8. Measurements of erythema, transepidermal water loss, stratum corneum water content, pH, and melanin were taken from fixed lesion sites on both cheeks before on week0, week4 and week8.
Researchers will compare differences in facial lipidomics and microbiomics between patients' lesion sites and the healthy population, as well as before and after the use of creams by patients to see whether the lipidomics and microbiomics at skin lesions are different in PAE patients compared to the healthy population and whether the intensive care cream has an improved effect on them.
This trial is a single-center, randomized controlled study. Eighty subjects are to be recruited. Subjects are divided into a healthy control group (20 people, healthy people without PAE and other inflammatory skin diseases on the face) and a test group (60 people, patients who meet the diagnostic criteria for PAE). Subjects avoided strenuous exercise and sweating for 3 hours before the test, and avoided the use of sunscreen, foundation and other cosmetics. The temperature of the test environment was controlled at 20-25°C and humidity at 45-50%.
At the time of enrollment, patients were informed of the precautions to be taken and signed an informed consent form. The healthy control group used CK sebaceous tape to adhere a 1-cm skin sample from the lateral side of the cheeks and nose at the level of both cheeks and noses for multi-histological testing (sebum, microbiology, and other histological analyses) in order to compare the facial histological differences between the healthy individuals and the patients with PAE.
The test group was 60 people, using the left and right half of the face in an auto-control manner, randomly selected to use the Winona Barrier Multi-Repair Cream on one cheek and the Base Cream on the other. One erythematous area on each cheek was selected at the time of enrollment, and skin elasticity was measured using Cutometer® Dual MPA580 (Courage+Khazaka, Germany), stratum corneum water content was measured using Corneometer CM825 (Courage+Khazaka, Germany), and water content of the stratum corneum was measured using Sebumeter® SM815 (Courage+Khazaka, Germany) for sebum content, Tewameter® (Courage+Khazaka, Germany) for transepidermal water loss (TEWL) and pH-Meter PH905 (Courage+Khazaka, Germany) for pH, Mexameter® MX18 (Courage+Khazaka, Germany) for melanin and erythema; L*, a*, b* values were measured with an L*a*b* colorimeter (Konica-Minolta, Japan); and skin samples were adhered to a CK sebaceous tape (Courage+Khazaka, Germany) for a multihistological test. (sebum, microorganisms, etc.); VISIA® (Canfield, USA) skin image analyzer was used to collect frontal, left and right photographs of the patient's face. The patients were followed up at weeks 4 and 8 to record any adverse reactions, and the above skin physiological parameters and dermatologic sampling were performed in the same erythematous area. Frontal, left and right photographs of the patient's face at the end of treatment were taken at week 8 using the VISIA® Skin Image Analyzer.
The efficacy of the treatment was assessed by comparing the differences between the treated and non-treated erythema, skin test indices, and histologic findings in control patients. The safety of the treatment was assessed by the presence or absence of adverse effects. The effect of treatment on skin metabolomics was also assessed by comparing skin metabolomic differences between PAE patients before and after treatment and with normal subjects.
Between March 2023 to May 2023, patients diagnosed with post-acne erythema and meeting the inclusion criteria were enrolled in the study from the Department of Dermatology at Jiangsu Provincial People's Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
the patients
Other: Treatment and control groups
The checks of patients were randomly selected to use winona barrier special cream on one side and the Basal Water on the other side. the sampes of surface skin are collected on week0, week4 and week8. Measurements of erythema, transepidermal water loss, stratum corneum water content, pH, and melanin were taken from fixed lesion sites on both cheeks before on week0, week4 and week8.
Global Aesthetic Improvement Scale (GAIS) score
The overall aesthetic improvement of facial skin will be assessed by a blinded evaluator using the Global Aesthetic Improvement Scale (GAIS). The GAIS score will be assigned to each side of the face according to the following criteria: -1 = worsened; 0 = no improvement; 1 = slight improvement; 2 = marked improvement; 3 = near complete recovery. The assessment will be performed at 3 days and 7 days after treatment.
Time frame: 3 days (T3d) and 7 days (T7d) after treatment
Transepidermal water loss (TEWL)
Transepidermal water loss (TEWL) will be measured using the GPSkin Barrier skin physiological measurement device (GPOWER, Republic of Korea). Measurements will be obtained at the predefined facial cheek site, located at the intersection of the vertical line through the center of the eye and the horizontal line through the center of the nasal bridge. TEWL will be recorded in g/(m²·h).
Time frame: Baseline (BL), immediately after treatment (Timm), 2 hours after treatment (T2h), 3 days after treatment (T3d), and 7 days after treatment (T7d)
Stratum corneum hydration (SCH)
Measurements will be obtained at the predefined facial cheek site, located at the intersection of the vertical line through the center of the eye and the horizontal line through the center of the nasal bridge.
Time frame: Baseline (BL), immediately after treatment (Timm), 2 hours after treatment (T2h), 3 days after treatment (T3d), and 7 days after treatment (T7d)
CIELAB a* value measured by colorimetry
The CIELAB a\* value of facial skin will be measured using a CM-700d spectrophotometer (Konica Minolta, Japan). Measurements will be obtained at the predefined facial cheek site, located at the intersection of the vertical line through the center of the eye and the horizontal line through the center of the nasal tip.
Time frame: Baseline (BL), immediately after treatment (Timm), 2 hours after treatment (T2h), 3 days after treatment (T3d), and 7 days after treatment (T7d)
Facial red area percentage assessed by VISIA imaging
Standardized facial images will be acquired using the VISIA facial imaging system (Canfield Scientific, USA), with imaging of the left, central, and right cheek regions. The percentage of facial red area will be quantitatively analyzed from the acquired images using Image-Pro Plus (IPP) software.
Time frame: Baseline (BL) and 7 days after treatment (T7d)
Ran from Apr 2023 to primary completion in Jul 2023, 3 months.
Of 38 observational studies under Acne Vulgaris, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 3 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Affiliated Hospital with Nanjing Medical University →